Hadassah

Thrombotech Receives Regulatory Approval for Stroke Medicine Trials in the US

Wednesday, Mar 28 2012

Thrombotech Ltd., a biotechnology company based on cutting-edge stroke research at the Hadassah University Medical Center, has received approval from the United States' Food and Drug Administration (FDA) to expand clinical trials to the US for its lead product, THR-18. This medicine is designed to improve the safety and efficacy of tPA, the currently available treatment for ischemic stroke.

THR-18 is designed to allow tPA to dissolve blood clots easily, extending its short therapeutic time window and diminishing life-threatening side effects. It is currently undergoing Phase IIA clinical trials at several hospitals in Israel, including Hadassah, and is awaiting regulatory approvals in Europe and India.

"This important regulatory approval serves as external validation for our development program and the quality of the science and management behind the company," says Thrombotech Chief Executive Officer Dr. Ruth Ben Yakar. "It will enable us to recruit more patients in some of the leading medical centers specializing in stroke in the US and move towards commercialization of the therapy for this serious medical condition."

Hadasit, Hadassah's technology transfer company, holds a 24% stake in Thrombotech. Commenting on the approval, Ophir Shahaf, Chief Executive Officer of Hadasit Bio-Holdings, Hadasit's publicly traded subsidiary, stated: "We are proud to expand the clinical trial to medical centers in the US, a world leader in Central Nervous System therapeutics and stroke treatment in particular."

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Sep 21 2018

Hadassah Numbers to Commend and Celebrate

Over the past year, Hadassah Medical Center researchers received over 60 percent of the National Science Foundation Awards for biomedical research in Israeli hospitals...

READ MORE ›
alt_text

Thursday, Sep 20 2018

NanoKnife® Technology to Treat Prostate Cancer Comes to Hadassah

NanoKnife® technology, the most innovative method for treatment of localized prostate cancer, is now being applied at the Hadassah Medical Organization, making Hadassah the first in Israel to treat prostate cancer in this minimally invasive way.

READ MORE ›
alt_text

Thursday, Sep 20 2018

Car-ramming Victim and His Family Give Thanks

Life in the Horaling family changed forever on November 17, 2017. Dad Ebenezer Horaling, 35, was taking a bus to work as a custodian at a boys’ junior high school 20 minutes away from his home. Ebenezer had gotten off the bus and was walking to the school when a 17-year-old terrorist drove into him, throwing him into the air.

READ MORE ›
alt_text

Thursday, Sep 20 2018

Hadassah Director General Organizes Surprise for Hospitalized Children

Providing a respite from medical treatment during this holiday season, a collection of antique cars suddenly appeared on the lawns of Hadassah Hospital Ein Kerem, and the hospitalized children and their families were invited to take a close look.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More